Last update 20 Mar 2025

Bivalent Subtype C gp120/AS01B vaccine(National Institute of Allergy & Infectious Diseases)

Overview

Basic Info

Drug Type
Prophylactic vaccine
Synonyms-
Target-
Action
stimulants
Mechanism
Immunostimulants
Therapeutic Areas
Immune System DiseasesInfectious DiseasesUrogenital Diseases
Active Indication-
Inactive Indication
HIV Infections
Originator Organization
National Institute of Allergy & Infectious Diseases
Active Organization-
Inactive Organization
National Institute of Allergy & Infectious Diseases
Drug Highest PhasePendingPhase 1/2
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with Bivalent Subtype C gp120/AS01B vaccine(National Institute of Allergy & Infectious Diseases)
NCT02915016
/ CompletedPhase 1/2IIT
A Phase 1/2a Clinical Trial to Evaluate the Safety and Immunogenicity of HIV Clade C DNA, and of MF59®- or AS01B-Adjuvanted Clade C Env Protein in Various Combinations, in Healthy, HIV-Uninfected Adult Participants
100 Clinical Results associated with Bivalent Subtype C gp120/AS01B vaccine(National Institute of Allergy & Infectious Diseases)
Login to view more data
100 Translational Medicine associated with Bivalent Subtype C gp120/AS01B vaccine(National Institute of Allergy & Infectious Diseases)
Login to view more data
100 Patents (Medical) associated with Bivalent Subtype C gp120/AS01B vaccine(National Institute of Allergy & Infectious Diseases)
Login to view more data
100 Deals associated with Bivalent Subtype C gp120/AS01B vaccine(National Institute of Allergy & Infectious Diseases)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
HIV InfectionsPhase 2
South Africa
National Institute of Allergy & Infectious Diseases
07 Dec 2016
HIV InfectionsPhase 2
United States
National Institute of Allergy & Infectious Diseases
07 Dec 2016
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT02915016 (HVTN108, CTgov)
Phase 1/2
HIV Infections
334
(Group 1: DNA-HIV-PT123 + Placebo + Protein/MF59)
doxscqgdyv(dwsyhhjntm) = eowuhzmeqq irtffoowly (yvetfrldjq, cqhdjoigjz - bdkbcfcwpx)
View more
-
16 Sep 2020
(Group 2: DNA-HIV-PT123 + Placebo + Protein/AS01B)
doxscqgdyv(dwsyhhjntm) = gosauksczm irtffoowly (yvetfrldjq, gvzdxuimrt - crmnxxcbit)
View more
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free